ALLMedicine™ Hypercalcemia Center

Jul 1st, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...

Jul 1st, 2022 - Familial multiple endocrine neoplasia type 1 (MEN1), familial hypocalciuric (or familial benign) hypercalcemia (FHH), hyperparathyroidism - jaw tumor syndrome (HPT-JT), other causes of familial isolated hyperparathyroidism (FIHP), and pseudohypopa...

Jun 30th, 2022 - Multiple myeloma (MM), Being one of the most common hematologic malignancies, particularly in the elderly patient, MM represents a devastating disease that occurs due to uncontrolled proliferation of a plasma cell in bone marrow , MM Presents itse...

Jun 28th, 2022 - Sarcoidosis is a systemic inflammatory disease of unknown etiology. The pathogenesis rests on an aberrant T cell response to unidentified antigens in individuals predisposed by genetic and environmental factors. Increased expression of polarized m...

Jun 28th, 2022 - Common electrolyte abnormalities in primary care: Hypercalcemia.|2022||etiology,

Jan 19th, 2019 - Adult T-cell leukemia-lymphoma (ATL) is a distinct mature T-cell malignancy caused by chronic infection with human T-lymphotropic virus type 1 with diverse clinical features and prognosis. ATL remains a challenging disease as a result of its diver...

Feb 12th, 2017 - Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-r...

Oct 12th, 2014 - Hydroelectrolytic disorders are one of the most common metabolic complications in cancer patients. Although often metabolic alterations affecting various ions are part of the manifestations of the oncological disease, even in the form of paraneopl...

Jul 1st, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...

Jul 1st, 2022 - Familial multiple endocrine neoplasia type 1 (MEN1), familial hypocalciuric (or familial benign) hypercalcemia (FHH), hyperparathyroidism - jaw tumor syndrome (HPT-JT), other causes of familial isolated hyperparathyroidism (FIHP), and pseudohypopa...

Jun 30th, 2022 - Multiple myeloma (MM), Being one of the most common hematologic malignancies, particularly in the elderly patient, MM represents a devastating disease that occurs due to uncontrolled proliferation of a plasma cell in bone marrow , MM Presents itse...

Jun 27th, 2022 - Treatment subjects: Patients will be identified and recruited when presenting with acute fracture to our medical center. Under routine care at our center, all cervical spine fractures are evaluated, either in person or via tele-consult for remote ...

Jun 27th, 2022 - This is a post-marketing drug intensive monitoring surveillance with an observational, non-interventional design. The objectives are to compare the incidence of hypercalcemia in patients with and without calcium intake (including dietary supplemen...

May 2nd, 2022 - The combination of nab-paclitaxel (Abraxane) and pembrolizumab (Keytruda) produced an encouraging overall response rate (ORR) with manageable safety in patients with advanced urothelial cancer who were refractory to platinum-based chemotherapy or ...

Apr 21st, 2022 - The FDA has granted an orphan drug designation to the PD-1 inhibitor toripalimab as a potential therapeutic option for patients with small cell lung cancer (SCLC), according to an announcement from Coherus BioSciences, Inc. and Shanghai Junshi Bio...

Apr 18th, 2022 - Patients who receive parathyroidectomy for mild primary hyperparathyroidism show no benefits in survival or morbidity, including fractures, cancer, or cardiovascular outcomes over more than 10 years, when compared with those not receiving the surg...

Jan 4th, 2022 - Multiple myeloma at a younger age did not portend more aggressive disease or worse outcomes but significantly shortened lifespan as compared with the general population without myeloma, according to one of the largest studies of its kind. Over a 1...

Dec 27th, 2021 - After decades of research, investigators are hopeful that the nonsteroidal selective androgen receptor (AR) agonist enobosarm could become an important treatment strategy following CDK4/6 inhibition in patients with AR-positive, estrogen receptor ...